HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
4.109
+0.109 (2.72%)
Jul 20, 2026, 10:48 AM EDT - Market open
HCW Biologics Revenue
HCW Biologics had revenue of $6.54M in the quarter ending March 31, 2026, with 129,080.67% growth. This brings the company's revenue in the last twelve months to $6.59M, up 356.16% year-over-year. In the year 2025, HCW Biologics had annual revenue of $54.23K, down -97.89%.
Revenue (ttm)
$6.59M
Revenue Growth
+356.16%
P/S Ratio
0.73
Revenue / Employee
$188,348
Employees
35
Market Cap
4.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.23K | -2.51M | -97.89% |
| Dec 31, 2024 | 2.57M | -275.00K | -9.68% |
| Dec 31, 2023 | 2.84M | -3.88M | -57.72% |
| Dec 31, 2022 | 6.72M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bio Green Med Solution | 1.53M |
| PMGC Holdings | 1.27M |
| Silo Pharma | 72.10K |
| Cardio Diagnostics Holdings | 16.57K |
| Alaunos Therapeutics | 3.00K |
| Soligenix | 2.34K |
HCWB News
- 20 days ago - HCW Biologics regains compliance with Nasdaq - TheFly
- 20 days ago - HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter - GlobeNewsWire
- 20 days ago - Hcw Biologics Inc trading halted, news pending - TheFly
- 24 days ago - HCW Biologics announces 1-for-6 reverse stock split - TheFly
- 24 days ago - HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 - GlobeNewsWire
- 4 weeks ago - HCW Biologics Registration statement: Registration filing - Filings
- 4 weeks ago - HCW Biologics announces data from first two dose cohorts of HCW9302 trial - TheFly
- 4 weeks ago - HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata - GlobeNewsWire